Table 4.
Subgroup analyses of pooled estimates of the crude incidence rate (per 100 person-years) and incidence rate ratio of HCC in patients treated with antiviral therapy (SVR vs. non-SVR) related to liver cirrhosis, HBsAg positivity, and Peg-IFN use.
| Studies | Incidence rate (per 100 person-years) | Incidence rate ratio | |
|---|---|---|---|
| Pooled estimate (95% CI) | Pooled estimate (95% CI) | ||
| SVR | Non-SVR | ||
| Liver cirrhosis | |||
| Included (n = 19) | 0.38 (0.33–0.44) | 1.71 (1.61–1.81) | 0.22 (0.19–0.26) |
| Excluded (n = 6) | 0.14 (0.04–0.56) | 1.61 (1.25–2.07) | 0.09 (0.02–0.35) |
| HBsAg positive | |||
| Included or unreported (n = 9) | 0.38 (0.28–0.53) | 1.80 (1.56–2.09) | 0.21 (0.15–0.30) |
| Excluded (n = 16) | 0.37 (0.32–0.43) | 1.68 (1.58–1.79) | 0.22 (0.19–0.26) |
| Peg-IFN | |||
| Other or unreported (n = 17) | 0.34 (0.29–0.41) | 1.67 (1.56–1.80) | 0.21 (0.17–0.25) |
| Included (n = 8) | 0.42 (0.34–0.51) | 1.75 (1.59–1.91) | 0.24 (0.19–0.30) |
HCC hepatocellular carcinoma, SVR sustained virologic response, Peg-IFN pegylated interferon, CI confidence interval.